Preclinical antitumor activity of batrac
โ
Jacqueline Plowman; Kenneth D. Paull; Ghanem Atassi; Steadman D. Harrison; Donal
๐
Article
๐
1988
๐
Springer US
๐
English
โ 471 KB
Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose of 400 mg/kg, inhibited tumor growth completely in 80-100~ of mice with early-stage colon adenocarcinoma 38. Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin al